Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × GIST × Sarcoma × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 68 Gastrointestinal Stromal Tumors 32 Glioblastoma 19 Gliosarcoma 18 Dendritic Cell Sarcoma, Interdigitating 17 Neoplasms 16 Liposarcoma 16 Bone Neoplasms 16 Rhabdomyosarcoma 14 Neoplasm Metastasis 14 Leiomyosarcoma 14 Lymphoma, Large B-Cell, Diffuse 13 Burkitt Lymphoma 13 Central Nervous System Neoplasms 12 Sarcoma, Synovial 11 Recurrence 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Histiocytoma, Malignant Fibrous 11 Osteosarcoma 10 Lymphoma 10 Hemangiosarcoma 10 Fibrosarcoma 10 Brain Neoplasms 10 Multiple Myeloma 9 Lymphoma, Non-Hodgkin 9 Lymphoma, Mantle-Cell 9 Lymphoma, Large-Cell, Immunoblastic 9 Lymphoma, Follicular 9 Lymphoma, B-Cell, Marginal Zone 9 Leukemia, Myeloid, Chronic-Phase 9

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡